Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,359 stopped studies mapped to Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,359 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02736357 | The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study(LEO) | — | withdrawn | Apr 13, 2016 | Mayo Clinic | Study restructured with Central IRB (NCT04996706); accruals reported there. | Enrollment / accrual |
| NCT02794246 | CART-19 Post-ASCT for Multiple Myeloma | Phase 2 | terminated | Jun 9, 2016 | University of Pennsylvania | Study was terminated due to administrative reasons. | Other (stated, no rule matched) |
| NCT03399448 | NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) | Phase 1 | terminated | Jan 16, 2018 | University of Pennsylvania | Sponsor has terminated trial to pursue other targets. | Other (stated, no rule matched) |
| NCT03782064 | Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With… | Phase 2 | terminated | Dec 20, 2018 | Beth Israel Deaconess Medical Center | Funding | Funding |
| NCT05037669 | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric… | Phase 1 | withdrawn | Sep 8, 2021 | University of Pennsylvania | No available investigational product | Other (stated, no rule matched) |
| NCT01378871 | A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T… | Phase 2 | terminated | Jun 23, 2011 | Amit Verma | IND withdrawn | Other (stated, no rule matched) |
| NCT04649060 | Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in…(LIGHTHOUSE) | Phase 3 | terminated | Dec 2, 2020 | Oncopeptides AB | The sponsor decided to terminate the study due to financial issues following an FDA request for a… | Funding |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid… | Phase 1 / Phase 2 | terminated | May 12, 2015 | Asana BioSciences | Business decision | Sponsor / business decision |
| NCT02516696 | BiRd vs. Rd as Initial Therapy in Multiple Myeloma(BiRd vs Rd) | Phase 3 | terminated | Aug 6, 2015 | Weill Medical College of Cornell University | low enrollment | Enrollment / accrual |
| NCT04502706 | Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in… | Phase 1 | terminated | Aug 6, 2020 | Gilead Sciences | Sponsor's decision to discontinue development of this molecule | Sponsor / business decision |
| NCT05127811 | A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma | Phase 1 | terminated | Nov 19, 2021 | Zentera Therapeutics HK Limited | Sponsor's decision | Sponsor / business decision |
| NCT05152459 | Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or… | Phase 1 / Phase 2 | withdrawn | Dec 9, 2021 | City of Hope Medical Center | Feasibility | Other (stated, no rule matched) |
| NCT02063113 | Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.(MYELOME-PA) | N/A | terminated | Feb 14, 2014 | Nantes University Hospital | inclusion difficulty | Other (stated, no rule matched) |
| NCT01579318 | Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma(CTCL) | Phase 2 | terminated | Apr 17, 2012 | OncoSec Medical Incorporated | Due to company resource constraints | Sponsor / business decision |
| NCT03850028 | Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution… | N/A | withdrawn | Feb 21, 2019 | University Medical Center Groningen | Closed prematurely because the accrual was not achieved | Enrollment / accrual |
| NCT01728259 | First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD | Phase 1 | terminated | Nov 19, 2012 | Barbara Ann Karmanos Cancer Institute | FDA placed the study on a clinical hold, due to the concerns by the FDA and Health Canada, Celgene… | Other (stated, no rule matched) |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | Phase 1 | terminated | Sep 26, 2016 | MEI Pharma, Inc. | discontinuation of zandelisib program | Other (stated, no rule matched) |
| NCT04161118 | TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive…(TIGER-CTL019) | Phase 2 | terminated | Nov 13, 2019 | University of Cologne | Termination of the funding agreement by the financial sponsor of the study. Small number of… | Safety / toxicity |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03999658 | A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected… | Phase 2 | withdrawn | Jun 27, 2019 | Sorrento Therapeutics, Inc. | Sorrento Therapeutics filed for chapter 11 bankruptcy. | Other (stated, no rule matched) |
| NCT04348006 | Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple…(MM) | Phase 4 | withdrawn | Apr 15, 2020 | Al-Rasheed University College | No patients were enrolled in the study | Enrollment / accrual |
| NCT04775680 | Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors… | Phase 1 / Phase 2 | terminated | Mar 1, 2021 | Adagene (Suzhou) Limited | The safety of ADG106 combined with triprilimab has been fully understood.The overall clinical… | Safety / toxicity |
| NCT05169151 | Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors… | — | withdrawn | Dec 23, 2021 | M.D. Anderson Cancer Center | 0 patient accrual | Enrollment / accrual |
| NCT05393999 | SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2…(SABRE) | Phase 2 | withdrawn | May 27, 2022 | Imperial College Healthcare NHS Trust | The drug was found to be ineffective against Omicron, so the study was terminated and no patients… | Enrollment / accrual |
| NCT05431179 | A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell… | Phase 3 | withdrawn | Jun 24, 2022 | Oncternal Therapeutics, Inc | Due to a strategic reprioritization based on the rapidly changing clinical and commercial landscape… | Sponsor / business decision |
| NCT03371420 | PET Imaging of Subjects Using 124I-PU-AD | Early Phase 1 | terminated | Dec 13, 2017 | Samus Therapeutics, Inc. | Company has ceased operations | Sponsor / business decision |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected… | Phase 1 | terminated | Mar 14, 2018 | Amgen | Strategic decisions | Sponsor / business decision |
| NCT04045028 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics… | Phase 1 | terminated | Aug 5, 2019 | Genentech, Inc. | Slow recruitment | Enrollment / accrual |
| NCT02890368 | Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory… | Phase 1 | terminated | Sep 7, 2016 | Pfizer | not stated | Not stated |
| NCT03411031 | Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on… | Phase 2 | terminated | Jan 25, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Sponsor no longer providing drug | Other (stated, no rule matched) |
| NCT01899326 | Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With… | N/A | terminated | Jul 15, 2013 | Albert Einstein College of Medicine | The study was stopped during the interim analysis due to low accrual after the widespread use of… | Efficacy / futility |
| NCT04075721 | First in Human Dose Escalation of M3258 as a Single Agent and Expansion Study of M3258 in… | Phase 1 | terminated | Sep 3, 2019 | EMD Serono Research & Development Institute, Inc. | The study was early discontinued due to lack of participant enrollment. | Enrollment / accrual |
| NCT05365100 | A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL | Phase 1 / Phase 2 | withdrawn | May 9, 2022 | BioNova Pharmaceuticals (Shanghai) LTD. | Due to company decision | Sponsor / business decision |
| NCT04635735 | Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory… | Phase 1 / Phase 2 | terminated | Nov 19, 2020 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT01316146 | Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART… | Phase 1 | withdrawn | Mar 16, 2011 | UNC Lineberger Comprehensive Cancer Center | Study never truly opened to accrual at UNC. Study and data were transfered to UNC as the IND for… | Enrollment / accrual |
| NCT04602065 | Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory… | Phase 1 / Phase 2 | terminated | Oct 26, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Due to the company's development strategy adjustment, Innovent Biologics has decided not to… | Sponsor / business decision |
| NCT04521335 | Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple…(Repurpose-1) | Phase 1 | terminated | Aug 20, 2020 | University of Utah | Closed at PI's Request | Other (stated, no rule matched) |
| NCT03639610 | PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM…(BRIDGE) | Phase 2 | terminated | Aug 21, 2018 | Oncopeptides AB | The sponsor decided to terminate the study following an FDA request of a partial clinical hold. | Sponsor / business decision |
| NCT03445663 | Study Evaluating AMG 424 in Subjects With Multiple Myeloma | Phase 1 | terminated | Feb 26, 2018 | Xencor, Inc. | Previous sponsor business decision not to proceed with the AMG 424 asset. | Sponsor / business decision |
| NCT04895410 | Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV)… | Phase 1 | terminated | May 20, 2021 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT04236141 | A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With… | Phase 3 | terminated | Jan 22, 2020 | Hoffmann-La Roche | Sponsor's decision, no safety concerns | Safety / toxicity |
| NCT05513612 | Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies | Phase 1 | withdrawn | Aug 24, 2022 | Shanghai Pudong Hospital | The study is not initiated and we want it to be withdrawn. | Other (stated, no rule matched) |
| NCT03370185 | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic…(BRIO) | Phase 2 | withdrawn | Dec 12, 2017 | SecuraBio | Reassessing corporate priorities. | Other (stated, no rule matched) |
| NCT02292225 | Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi… | Phase 1 | terminated | Nov 17, 2014 | SecuraBio | The scope of the program has been reduced to focus resources on studies which can potentially… | Other (stated, no rule matched) |
| NCT02807454 | A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and…(FUSIONMM-003) | Phase 2 | terminated | Jun 21, 2016 | Celgene | Health Authority request due to class effect | Other (stated, no rule matched) |
| NCT04021082 | CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory… | Phase 2 / Phase 3 | withdrawn | Jul 16, 2019 | Portola Pharmaceuticals | Sponsor decision to not initiate the trial | Sponsor / business decision |
| NCT05176691 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | Phase 1 | withdrawn | Jan 4, 2022 | Hutchmed | HUTCHMED has decided to discontinue the HMPL 760 study. | Other (stated, no rule matched) |
| NCT03123393 | TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | terminated | Apr 21, 2017 | Calithera Biosciences, Inc | Lack of efficacy of the drug; no safety concern | Safety / toxicity |
| NCT03238651 | A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin… | Phase 1 | terminated | Aug 3, 2017 | Calithera Biosciences, Inc | Termination of the study by the sponsor due to business decision. | Sponsor / business decision |
| NCT03772288 | A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin… | Phase 1 | withdrawn | Dec 11, 2018 | Calithera Biosciences, Inc | Business Decision: No Safety or Efficacy Concerns | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jun 22, 2023source: clinicaltrials